Web of Science: 16 citations, Scopus: 16 citations, Google Scholar: citations,
A novel truncated form of apolipoprotein A-I transported by dense LDL is increased in diabetic patients
Cubedo, Judit (Institut d'Investigació Biomèdica Sant Pau)
Padró, Teresa (Institut d'Investigació Biomèdica Sant Pau)
García-Arguinzonis, Maisa (Institut d'Investigació Biomèdica Sant Pau)
Vilahur, Gemma (Institut d'Investigació Biomèdica Sant Pau)
Miñambres, Inka (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Pou, Josep Maria (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Ybarra, Juan (Teknon Medical Center)
Badimon, Lina (Institut d'Investigació Biomèdica Sant Pau)
Universitat Autònoma de Barcelona. Departament de Medicina

Date: 2015
Abstract: Diabetic (DM) patients have exacerbated atherosclerosis and high CVD burden. Changes in lipid metabolism, lipoprotein structure, and dysfunctional HDL are characteristics of diabetes. Our aim was to investigate whether serum ApoA-I, the main protein in HDL, was biochemically modified in DM patients. By using proteomic technologies, we have identified a 26 kDa ApoA-I form in serum. MS analysis revealed this 26 kDa form as a novel truncated variant lacking amino acids 1-38, ApoA-IΔ(1-38). DM patients show a 2-fold increase in ApoA-IΔ(1-38) over nondiabetic individuals. ApoA-IΔ(1-38) is found in LDL, but not in VLDL or HDL, with an increase in LDL3 and LDL4 subfractions. To identify candidate mechanisms of ApoA-I truncation, we investigated potentially involved enzymes by in silico data mining, and tested the most probable molecule in an established animal model of diabetes. We have found increased hepatic cathepsin D activity as one of the potential proteases involved in ApoA-I truncation. Cathepsin D-cleaved ApoA-I exhibited increased LDL binding affinity and decreased antioxidant activity against LDL oxidation. In conclusion, we show for the first time: a) presence of a novel truncated ApoA-I form, ApoA-IΔ(1-38), in human serum; b) ApoA-IΔ(1-38) is transported by LDL; c) ApoA-IΔ(1-38) is increased in dense LDL fractions of DM patients; and d) cathepsin D-ApoA-I truncation may lead to ApoA-IΔ(1-38) binding to LDLs, increasing their susceptibility to oxidation and contributing to the high cardiovascular risk of DM patients.
Grants: Ministerio de Economía y Competitividad SAF2013-42962-R
Ministerio de Economía y Competitividad SAF2012-40208
Ministerio de Economía y Competitividad RD12/0019/0026
Ministerio de Economía y Competitividad RD12/0042/0027
Rights: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Language: Anglès
Document: Article ; recerca ; Versió publicada
Subject: Diabetes ; Hyperglycemia ; Low density lipoprotein ; Proteomics
Published in: Journal of Lipid Research, Vol. 56 Núm. 9 (january 2015) , p. 1762-1773, ISSN 1539-7262

DOI: 10.1194/jlr.P057513
PMID: 26168996


12 p, 1.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles

 Record created 2024-07-25, last modified 2024-12-19



   Favorit i Compartir